Breathe BioMedical Inc. (BRTH)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	57.36M
Revenue (ttm)	n/a
Net Income	-7.64M
EPS	-0.67
Shares Out	11.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About BRTH

Breathe BioMedical is a medical technology company focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue. Breathe BioMedical is in the development stage of our Breast Cancer Breath Test. Over the next two years we have verification and validation studies planned for the components and the Breast Cancer Breath Test, as well as a large multi-center clinical study planned to evaluate the safety and efficacy of the Breast Cancer Breath Test...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: BRTH
• Website: https://breathebiomedical.com/

Financial Performance

Financial numbers in CAD

Data Source: SEC filings Last updated: Aug 17, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error